Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.

Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.

We investigated whether therapeutic vaccination in highly active antiretroviral therapy (HAART)-treated patients with a modified vaccinia virus Ankara-vectored HIV-1 vaccine, with or without therapy interruption, induced the production of interleukin (IL)-10. Plasma IL-10 levels were not significant...

Bibliográfalaš dieđut
Váldodahkkit:	Yang, H, Guimarães-Walker, A, Hibbs, S, Dong, T, Stacey, A, Borrow, P, Hanke, T, Davenport, M, McMichael, A, Dorrell, L
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2009

Geahča maid

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
Dahkki: Touloumi, G, et al.
Almmustuhtton: (2006)

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
Dahkki: Angus, B, et al.
Almmustuhtton: (2008)

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
Dahkki: Dorrell, L, et al.
Almmustuhtton: (2005)

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.
Dahkki: Mocroft, A, et al.
Almmustuhtton: (2009)

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Dahkki: Gondim, MVP, et al.
Almmustuhtton: (2021)

Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
Dahkki: Yang, H, et al.
Almmustuhtton: (2007)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Dahkki: Gossez, M, et al.
Almmustuhtton: (2018)

Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
Dahkki: Wainwright, E, et al.
Almmustuhtton: (2013)

Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial
Dahkki: Lewis, J, et al.
Almmustuhtton: (2017)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
Dahkki: Dorrell, L, et al.
Almmustuhtton: (2007)

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: The role of interleukin 7 and interleukin 7 receptor alpha and microbial translocatioa
Dahkki: Rajasuriar, R., et al.
Almmustuhtton: (2010)

Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
Dahkki: Gibb, D, et al.
Almmustuhtton: (2004)

Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA
Dahkki: Natella Rakhmanina, et al.
Almmustuhtton: (2016-01-01)

Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
Dahkki: Abbas, U, et al.
Almmustuhtton: (2002)

Monitoring of highly active antiretroviral therapy in HIV infection.
Dahkki: Walker, A, et al.
Almmustuhtton: (2011)

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Dahkki: Gunst, JD, et al.
Almmustuhtton: (2025)

Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion.
Dahkki: Tin Phan, et al.
Almmustuhtton: (2024-07-01)

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Dahkki: Jesper D. Gunst, et al.
Almmustuhtton: (2025-01-01)

Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Dahkki: Boris Julg, et al.
Almmustuhtton: (2024-05-01)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Dahkki: Hancock, G, et al.
Almmustuhtton: (2017)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
Dahkki: Hakim, J, et al.
Almmustuhtton: (2017)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
Dahkki: Paton, N, et al.
Almmustuhtton: (2014)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
Dahkki: Hanke, T, et al.
Almmustuhtton: (2007)

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
Dahkki: Fidler, S, et al.
Almmustuhtton: (2020)

Response to combination antiretroviral therapy: variation by age.
Dahkki: Sabin, C, et al.
Almmustuhtton: (2008)

How soon after HIV seroconversion is antiretroviral therapy initiated?
Dahkki: Babiker, A, et al.
Almmustuhtton: (1999)

Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy.
Dahkki: Gay, C, et al.
Almmustuhtton: (2011)

Electronic Medical Record Data Missingness and Interruption in Antiretroviral Therapy Among Adults and Children Living With HIV in Haiti: Retrospective Longitudinal Study
Dahkki: Andrew M Secor, et al.
Almmustuhtton: (2024-03-01)

Cases inefficient antiretroviral therapy for HIV-1 in children
Dahkki: Yu. V. Ostankova, et al.
Almmustuhtton: (2017-06-01)

Challenges in Initiating Antiretroviral Therapy in 2010
Dahkki: Cécile L Tremblay, et al.
Almmustuhtton: (2010-01-01)

Current antiretroviral therapy: A review
Dahkki: Alexey V. Kravchenko, et al.
Almmustuhtton: (2023-12-01)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
Dahkki: Hanke, T, et al.
Almmustuhtton: (2008)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Dahkki: Paton, N, et al.
Almmustuhtton: (2014)

Antiretroviral therapy in Malaysia: identifying barriers to universal access
Dahkki: Kamarulzaman, A.
Almmustuhtton: (2009)

Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom
Dahkki: Ming J. Lee, et al.
Almmustuhtton: (2023-12-01)

Universal voluntary HIV testing and immediate antiretroviral therapy.
Dahkki: Jaffe, H, et al.
Almmustuhtton: (2009)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
Dahkki: Szubert, A, et al.
Almmustuhtton: (2015)

Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment
Dahkki: Damani A. Piggott, et al.
Almmustuhtton: (2011-01-01)

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
Dahkki: V. I. Petrov, et al.
Almmustuhtton: (2022-04-01)

Efficacy of antituberculosis therapy in combination with antiretroviral therapy in patients with co-infection TB/HIV
Dahkki: Kryzhanovsky D.G., et al.
Almmustuhtton: (2013-03-01)